MAGEA3 and non-small cell lung carcinoma: Moreover, a large randomized phase III trial with adjuvant MAGE-A3 vaccine after adjuvant chemotherapy in patients with resected stage IB through IIIA MAGE-A3 positive NSCLC failed to meet its primary endpoint [41].